EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Open-Label Sulforaphane Trial in FMR1 Premutation Carriers with Fragile-X-Associated Tremor and Ataxia Syndrome (FXTAS)

Ellery Santos iD, Courtney Clark, Hazel Maridith B Biag, Si Jie Tang iD, Kyoungmi Kim, Matthew D Ponzini iD, Andrea Schneider iD, Cecilia Giulivi iD, Federica Alice Maria Montanaro iD, Jesse Tran-Emilia Gipe, Jacquelyn Dayton, Jamie L Randol und 7 weitere

Cells · 2023

DOI: 10.3390/cells12242773 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Ellery Santos und 18 weiteren Autor:innen. Beteiligte Einrichtung: Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis Health, Sacramento, CA 95817, USA. Hauptthemen laut MEDLINE: Leukocytes, Mononuclear, Tremor. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, NINDS NIH HHS, NICHD HD036071.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fragile X (FMR1) premutation is a common mutation that affects about 1 in 200 females and 1 in 450 males and can lead to the development of fragile-X-associated tremor/ataxia syndrome (FXTAS). Although there is no targeted, proven treatment for FXTAS, research suggests that sulforaphane, an antioxidant present in cruciferous vegetables, can enhance mitochondrial function and maintain redox balance in the dermal fibroblasts of individuals with FXTAS, potentially leading to improved cognitive function. In a 24-week open-label trial involving 15 adults aged 60–88 with FXTAS, 11 participants successfully completed the study, demonstrating the safety and tolerability of sulforaphane. Clinical outcomes and biomarkers were measured to elucidate the effects of sulforaphane. While there were nominal improvements in multiple clinical measures, they were not significantly different after correction for multiple comparisons. PBMC energetic measures showed that the level of citrate synthase was higher after sulforaphane treatment, resulting in lower ATP production. The ratio of complex I to complex II showed positive correlations with the MoCA and BDS scores. Several mitochondrial biomarkers showed increased activity and quantity and were correlated with clinical improvements.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukocytes, MononuclearTremorAdultMaleFragile X Messenger Ribonucleoprotein 1FemaleHumansAtaxiaBiomarkersSulfoxidesIsothiocyanatesFragile X Syndrome

Stichwörter der Autor:innen

FMR1FXTASneurodegenerationsulforaphane

Substanzen

Fragile X Messenger Ribonucleoprotein 1BiomarkerssulforaphaneSulfoxidesIsothiocyanatesFMR1 protein, human

Autor:innen und Institutionen

  • Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis Health, Sacramento, CA 95817, USA.
  • Department of Pediatrics, School of Medicine, University of California, Davis, CA 95817, USA.
  • Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, CA 95616, USA.
  • Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, CA 95616, USA.
  • Child and Adolescent Neuropsychiatry Unit, Department of Neuroscience, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Department of Education, Psychology, Communication, University of Bari Aldo Moro, 70121 Bari, Italy.

ORCID-Profile: Ellery Santos, Si Jie Tang, Matthew D Ponzini, Andrea Schneider, Cecilia Giulivi, Federica Alice Maria Montanaro, Pamela J Yao, Apostolos Manolopoulos, Dimitrios Kapogiannis, Randi Hagerman, Flora Tassone

Förderung

  • NICHD NIH HHS
  • NINDS NIH HHS
  • NICHD HD036071
  • the Intellectual and Developmental Disability Research Center grant from NICHD P50 HD103526
  • Phillips Foundation
  • Vic LaFave Sr Foundation
  • Tides Foundation
  • Intramural Research Program of the National Institute on Aging, NIH

Zitieren

APA

Santos, E., Clark, C., Biag, H. M. B., Tang, S. J., Kim, K., Ponzini, M. D., Schneider, A., Giulivi, C., Montanaro, F. A. M., Gipe, J. T., Dayton, J., Randol, J. L., Yao, P. J., Manolopoulos, A., Kapogiannis, D., Hwang, Y. H., Hagerman, P., Hagerman, R., & Tassone, F. (2023). Open-Label Sulforaphane Trial in FMR1 Premutation Carriers with Fragile-X-Associated Tremor and Ataxia Syndrome (FXTAS). Cells. https://doi.org/10.3390/cells12242773

Vancouver

Santos E, Clark C, Biag HMB, Tang SJ, Kim K, Ponzini MD, et al. Open-Label Sulforaphane Trial in FMR1 Premutation Carriers with Fragile-X-Associated Tremor and Ataxia Syndrome (FXTAS). Cells. 2023. doi:10.3390/cells12242773

BibTeX
@article{Santos2023,
  author = {Santos, Ellery and Clark, Courtney and Biag, Hazel Maridith B and Tang, Si Jie and Kim, Kyoungmi and Ponzini, Matthew D and Schneider, Andrea and Giulivi, Cecilia and Montanaro, Federica Alice Maria and Gipe, Jesse Tran-Emilia and Dayton, Jacquelyn and Randol, Jamie L and Yao, Pamela J and Manolopoulos, Apostolos and Kapogiannis, Dimitrios and Hwang, Ye Hyun and Hagerman, Paul and Hagerman, Randi and Tassone, Flora},
  title = {Open-Label Sulforaphane Trial in FMR1 Premutation Carriers with Fragile-X-Associated Tremor and Ataxia Syndrome (FXTAS)},
  journal = {Cells},
  year = {2023},
  doi = {10.3390/cells12242773}
}
Kostenlos starten →